Stay updated on SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial

Sign up to get notified when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    This updates the page’s technical revision/version label to v3.5.3 from v3.5.2, with no visible change to the study record details presented.
    Difference
    0.0%
    Check dated 2026-04-25T17:52:44.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    Page revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-18T13:15:48.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    Added 'Squamous cell carcinoma of the head and neck' to the content and included a new Resources link to the Genetic and Rare Diseases Information Center.
    Difference
    0.1%
    Check dated 2026-03-27T21:59:36.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Revision stamp updated to v3.5.0, replacing the previous v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-20T19:35:39.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-06T14:57:23.000Z thumbnail image
  8. Check
    85 days ago
    Change Detected
    Summary
    The page revision was updated from v3.4.1 to v3.4.2. No user-facing content or functionality was altered.
    Difference
    0.0%
    Check dated 2026-02-12T15:45:55.000Z thumbnail image

Stay in the know with updates to SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SBRT +/- Pembrolizumab in Head and Neck Carcinoma Clinical Trial page.